Cargando...
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
The treatment of patients with myelodysplastic syndromes (MDSs) has hinged primarily on supportive care (ie, blood transfusions, colony stimulating agents, iron chelation, etc.) and the US Food and Drug Administration-approved agents, including 5-azacytidine, deoxyazacytidine, and lenalidomide. For...
Gardado en:
| Publicado en: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society of Hematology
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142467/ https://ncbi.nlm.nih.gov/pubmed/27913518 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|